Memorial Sloan Kettering Cancer Center
The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how people make choices about their health care, including about methods to screen for prostate cancer. Researchers are also doing this study to learn about how the genetic risk modifier test affects people's thoughts and feelings.
Inclusion Criteria: * Documentation of Disease o Patients must not have prostate cancer (for individuals not presently receiving care at the study site, this information will be based on self-report.) * Age between 45 - 70; * Assigned male sex at birth for individuals not presently receiving care at the study site, this information will be based on self-report.) * Completed full sequence or targeted genetic testing with a result confirmed in a clinically approved laboratory showing a BRCA1/2 likely pathogenic or pathogenic variant identified, or clinician note documents a BRCA1/2 likely pa…
swab sample in person or at home with a mailed test kit and will fill out a survey
about 1 week, 6 months, and 12 months after getting the updated cancer risk assessment to complete additional surveys.
for research testing
Arctuva estimate
Verify or correct the compensation shown for this listing.